Savara (SVRA) Amortization of Deferred Charges (2015 - 2026)
Savara (SVRA) posted quarterly Amortization of Deferred Charges of $42000.0 for Q1 2026, down 40.0% year-over-year from $70000.0 in Q1 2025, and down 87.46% quarter-over-quarter from $335000.0 in Q4 2025.
Powered by 
Analysis
Savara (SVRA) Amortization of Deferred Charges (2015 - 2026) Analysis & Trends
Savara (SVRA) has reported Amortization of Deferred Charges for 12 consecutive years, with $42000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 40.0% year-over-year to $42000.0; the TTM figure through Mar 2026 stood at $425000.0 (up 55.68% YoY), while the FY2025 annual figure was $453000.0, up 67.16% from the prior year.
- Amortization of Deferred Charges declined to $42000.0 in Q1 2026 per SVRA's latest filing, from $335000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $335000.0 in Q4 2025 and bottomed at -$87000.0 in Q2 2022.
- Historically, Amortization of Deferred Charges has averaged $69000.0 across 5 years, with a median of $68000.0 in 2023.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges plunged 163.5% — and 2025, when it jumped 4200.0%.
- Savara's Amortization of Deferred Charges stood at $35000.0 in 2022, then soared by 94.29% to $68000.0 in 2023, then changed by 0.0% to $68000.0 in 2024, then surged by 392.65% to $335000.0 in 2025, then sank by 87.46% to $42000.0 in 2026.
- Business Quant data shows SVRA's Amortization of Deferred Charges at $42000.0 in Q1 2026, $335000.0 in Q4 2025, and -$81000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 43,000.00 |
| Mar 31, 2026 | 160,000.00 |
| Dec 31, 2025 | 126,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Jun 30, 2025 | 129,000.00 |
| Mar 31, 2025 | 70,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 67,000.00 |
| Mar 31, 2024 | 68,000.00 |
| Dec 31, 2023 | 68,000.00 |
| Sep 30, 2023 | 68,000.00 |
| Jun 30, 2023 | 67,000.00 |
| Mar 31, 2023 | 68,000.00 |
| Dec 31, 2022 | 68,000.00 |
| Sep 30, 2022 | 68,000.00 |
| Jun 30, 2022 | 45,000.00 |
| Mar 31, 2022 | 153,000.00 |
| Dec 31, 2021 | 139,000.00 |
| Sep 30, 2021 | 136,000.00 |